Inhibitor Therapeutics, Inc. — Income Charts
11 years of history · ending 2022-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↓-100.0% -$14K
$0
R&D↓-99.5% -$1M
$6K
D&A
$0
Operating Income↑+76.1% +$2M
$-658K
EBITDA↑+76.1% +$2M
$-658K
Interest Expense
$23K
Other Income/Expense
$13M
Pretax Income
$12M
Tax Provision
$55K
Net Income↑+542.9% +$15M
$12M
Operating Margin
-32539.1%
Net Margin
-32439.1%
Effective Tax Rate
0.5%
Deferred Tax Assets
$0
Deferred Tax Liabilities
$55K
DTA Valuation Allowance↓-37.2% -$3M
$5M
Tax Credit Carryforwards↓-76.9% -$261K
$78K
NOL Carryforwards↓-39.8% -$3M
$4M
ETR Federal Statutory
—
ETR State + Local (pp)
—
Operating Lease Cost
—
Revenue YoY Variation
-100.0%
Income YoY Variation↓-142.0pts
-102.2%